Assignment – Dispute putting a price on biotech

In a letter to the editor of Nat. Biotech. Harrison and Lerer responded to the article of Stewart et al. and described that in their view the risk-adjusted Net Present Value (rNPV) model has two shortcomings that can put a biotechnology venture at a disadvantage in funding negotiations.